LAWSUITS FILED AGAINST PRA, ENDP and JCOM - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
Back to Newsroom
Mentioned in this Article

LAWSUITS FILED AGAINST PRA, ENDP and JCOM - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

Monday, August 17, 2020 1:40 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 17, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

ProAssurance Corporation (NYSE:PRA)

CONTACT JAKUBOWITZ ABOUT PRA:
https://claimyourloss.com/securities/proassurance-corporation-loss-submission-form/?id=8627&from=1

Class Period: April 26, 2019 - May 7, 2020

Lead Plaintiff Deadline: August 17, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) ProAssurance lacked adequate underwriting process and risk management controls necessary to set appropriate loss reserves in its Specialty P&C segment; (ii) ProAssurance failed to properly assess a large national healthcare account that experienced losses far exceeding the assumptions made when the account was underwritten; and (iii) as a result, ProAssurance was subject to materially heightened risk of financial loss and reserve charges.

Endo International Plc (NASDAQ:ENDP)

CONTACT JAKUBOWITZ ABOUT ENDP:
https://claimyourloss.com/securities/endo-international-plc-loss-submission-form/?id=8627&from=1

Class Period: August 8, 2017 - June 10, 2020

Lead Plaintiff Deadline: August 18, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

J2 Global, Inc. (NASDAQ:JCOM)

CONTACT JAKUBOWITZ ABOUT JCOM:
https://claimyourloss.com/securities/j2-global-inc-loss-submission-form/?id=8627&from=1

Class Period: October 5, 2015 - June 29, 2020

Lead Plaintiff Deadline: September 8, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) J2 Global engaged in undisclosed related party transactions; (2) J2 Global used misleading accounting to hide requisite impairments and underperformance in acquisitions; (3) several so-called independent members of the Company' board of directors and audit committee were not disinterested; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Jakubowitz Law
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions